Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Alexion plans to initiate pivotal phase III CHAMPION-ALS study of Ultomiris in ALS

Jan. 15, 2020

Kannalife presents additional data regarding the MOA of its leading candidate KLS-13019

Jan. 15, 2020

Neos studies NT-0502 in pilot phase I trial for chronic sialorrhea

Jan. 14, 2020

FDA approves Valtoco as acute treatment for seizures

Jan. 14, 2020

Methylphenidate improves executive functioning in patients with VCI

Jan. 14, 2020

PTC Therapeutics describes new compounds for treating Huntington's disease

Jan. 14, 2020

AMO Pharma opens enrollment in pivotal trial of AMO-02 for congenital myotonic dystrophy

Jan. 14, 2020

Stem cell-based approach to spinal cord injuries developed

Jan. 14, 2020

Human proteomics study gives new AD insights

Jan. 14, 2020

New REPAIR-MS phase II study begins with CNM-Au8 for MS

Jan. 13, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...